BCM
CORT icon

Brasada Capital Management’s Corcept Therapeutics CORT Stock Holding History

Brasada Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$36K – 262
2017
Q4 		$36K Buy
+2,000
New +$36.2K 0.01% 203

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Brasada Capital Management's CORT Position: Q1 2018 in Review

Brasada Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2018, closing a stake of 2,000 shares — an estimated $36K sold.

Brasada Capital Management first reported a position in CORT in Q4 2017 and held it in 1 quarter. The position peaked at $36K in Q4 2017. 212 funds tracked by Wall St. Rank hold CORT as of Q1 2018.

  • Brasada Capital Management reported no remaining Corcept Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Brasada Capital Management sold 2,000 Corcept Therapeutics shares in Q1 2018, an estimated $36K.
  • Brasada Capital Management first reported a position in Corcept Therapeutics in Q4 2017 and held it in 1 quarter.
  • Brasada Capital Management's Corcept Therapeutics position peaked at $36K in Q4 2017.
  • 212 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2018.

Based on Brasada Capital Management's 13F filing for Q1 2018, filed 15 May 2018.